tiprankstipranks
Trending News
More News >
Mustgrow Biologics Corp. (MGROF)
:MGROF

MustGrow Biologics (MGROF) AI Stock Analysis

Compare
11 Followers

Top Page

MustGrow Biologics (MGROF) vs. SPDR S&P 500 ETF (SPY)

MustGrow Biologics Business Overview & Revenue Model

Company DescriptionMustGrow Biologics Corp., an agricultural biotech company, focuses om development and commercialization of natural biopesticide, biofumigants, and bioherbicides derived from mustard seed. It provides preplant soil biofumigation, a technology to treat soil-borne diseases and pests for various crops, including fruit, vegetables, and other crops. The company is also developing bioherbicide to treat unwanted plant growth for use in organic agriculture, home, and garden markets, as well as agriculture markets; and postharvest food preservation, an application in sprout, disease, and pathogen treatment for storage and food preservation markets. In addition, it focuses on providing CannaPM, an active ingredient to treat fungal soil diseases, as well as foliar diseases. The company was formerly known as Duport Capital Ltd. and changed its name to MustGrow Biologics Corp. in March 2018. MustGrow Biologics Corp. was incorporated in 2014 and is headquartered in Saskatoon, Canada.
How the Company Makes Money

MustGrow Biologics Financial Statement Overview

Summary
MustGrow Biologics is experiencing substantial revenue growth and boasts strong gross margins and low leverage. However, the persistent net losses and negative cash flow highlight ongoing financial challenges that need addressing for long-term sustainability.
Income Statement
55
Neutral
MustGrow Biologics has shown significant revenue growth in the TTM period compared to previous years, driven by a substantial increase from 2023 to 2024. The gross profit margin is remarkably high at approximately 98.76% for the TTM, reflecting strong operational efficiency. However, the company is still facing challenges with profitability, as indicated by negative net income and EBITDA, suggesting that while revenue is growing, profitability remains elusive.
Balance Sheet
60
Neutral
The balance sheet reveals a strong equity position with a significant equity ratio of 78.15% in the TTM, indicating financial stability. The debt-to-equity ratio is low at 0.15, suggesting conservative leverage. However, a decline in stockholders' equity over the years and ongoing net losses pose potential risks to financial sustainability.
Cash Flow
50
Neutral
The cash flow analysis indicates ongoing negative free cash flow, which raises concerns about the company's ability to generate cash from operations. The operating cash flow to net income ratio is negative, reflecting challenges in converting income into cash. However, the company has managed to maintain cash reserves, likely from financing activities, providing some liquidity cushion.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
398.02K4.71M6.48K12.87K0.00
Gross Profit
300.75K4.33M6.48K12.87K0.00
EBIT
-5.11M-804.99K-5.56M-3.01M-3.37M
EBITDA
-5.11M-676.94K-5.56M-3.01M-3.26M
Net Income Common Stockholders
-4.89M-676.94K-5.57M-3.06M-3.36M
Balance SheetCash, Cash Equivalents and Short-Term Investments
3.00M6.82M7.02M9.62M3.31M
Total Assets
5.42M6.94M7.13M9.70M3.37M
Total Debt
517.99K759.33K759.33K749.27K902.24K
Net Debt
-2.48M-6.06M-6.26M-8.87M-2.41M
Total Liabilities
3.25M1.35M1.90M1.25M1.05M
Stockholders Equity
2.17M5.58M5.24M8.46M2.32M
Cash FlowFree Cash Flow
-3.58M-294.76K-3.26M-2.41M-2.58M
Operating Cash Flow
-3.58M-294.76K-3.26M-2.41M-2.58M
Investing Cash Flow
0.000.000.000.000.00
Financing Cash Flow
-241.34K95.75K653.75K8.72M1.86M

MustGrow Biologics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$32.01M-201.16%
51
Neutral
$2.02B-1.14-21.37%3.64%2.88%-30.57%
TSBEE
C$1.02M
C$1.95M
TSNPK
46
Neutral
C$26.33M-32.62%-39.06%-9.07%
TSKRN
43
Neutral
C$8.53M-35.90%-16.48%
$8.30M-32.32%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MGROF
MustGrow Biologics
0.62
-0.10
-13.89%
TSE:BEE
Bee Vectoring Technologies International
0.01
-0.01
-50.00%
TSE:GROW
CO2 Gro Inc
0.02
0.00
0.00%
TSE:KRN
Karnalyte Resources
0.17
0.03
21.43%
TSE:NPK
Verde Agritech
0.50
-0.47
-48.45%
VVIVF
EarthRenew
0.06
0.02
50.00%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.